Holen Sie sich die Stockscreener-App
2.965
3.19%
0.095
Schlusskurs vom Vortag:
$2.87
Offen:
$2.89
24-Stunden-Volumen:
337.10K
Relative Volume:
0.36
Marktkapitalisierung:
$376.29M
Einnahmen:
$433.14M
Nettoeinkommen (Verlust:
$4.95M
KGV:
83.05
EPS:
0.0357
Netto-Cashflow:
$6.55M
1W Leistung:
-27.94%
1M Leistung:
-24.06%
6M Leistung:
-41.12%
1J Leistung:
-41.24%
1-Tages-Spanne:
$2.87
$2.995
1-Wochen-Bereich:
$2.81
$4.13
52-Wochen-Spanne:
$2.6101
$7.0771
Organogenesis Holdings Inc Stock (ORGO) Company Profile
Firmenname
Organogenesis Holdings Inc
Sektor
Telefon
781-575-0775
Adresse
85 DAN ROAD, CANTON, MA
Compare ORGO vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ORGO
Organogenesis Holdings Inc
|
2.965 | 364.24M | 433.14M | 4.95M | 6.55M | 0.0357 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.21 | 57.12B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
126.80 | 53.16B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.46 | 47.25B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.52 | 37.59B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
489.64 | 21.85B | 3.13B | 1.27B | 1.12B | 26.39 |
Organogenesis Holdings Inc Stock (ORGO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-06-28 | Eingeleitet | Lake Street | Buy |
| 2024-02-07 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-06-15 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2023-05-24 | Hochstufung | BTIG Research | Neutral → Buy |
| 2022-11-10 | Herabstufung | BTIG Research | Buy → Neutral |
| 2022-08-10 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-01-10 | Eingeleitet | SVB Leerink | Outperform |
| 2019-08-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2019-05-02 | Eingeleitet | Credit Suisse | Outperform |
| 2019-04-17 | Eingeleitet | Oppenheimer | Outperform |
| 2019-04-11 | Eingeleitet | SunTrust | Buy |
Alle ansehen
Organogenesis Holdings Inc Aktie (ORGO) Neueste Nachrichten
Organogenesis (ORGO) VP amends Form 4 for equity grant and tax withholding - Stock Titan
ORGO (Organogenesis) CEO amends Form 4 for stock grant and tax share disposal - Stock Titan
[Form 4/A] Organogenesis Holdings Inc. Amended Insider Trading Activity - Stock Titan
Organogenesis (ORGO) VP updates Form 4 for award vesting and tax shares - Stock Titan
Organogenesis (NASDAQ: ORGO) officer amends Form 4 for award and tax-withheld shares - Stock Titan
Organogenesis Holdings Inc. (NASDAQ:ORGO) Q4 2025 Earnings Call Transcript - Insider Monkey
ORGO PE Ratio & Valuation, Is ORGO Overvalued - Intellectia AI
Wall Street Zen Downgrades Organogenesis (NASDAQ:ORGO) to Hold - MarketBeat
Organogenesis Holdings Inc. (ORGO) Stock Analysis: Unveiling a Potential 116% Upside in Healthcare Innovation - DirectorsTalk Interviews
Organogenesis (ORGO) CAO files Form 3 detailing stock and RSUs - Stock Titan
Organogenesis (NASDAQ:ORGO) Price Target Cut to $8.00 by Analysts at BTIG Research - MarketBeat
Organogenesis Holdings (ORGO) Margin-Driven Profitability Shift Tests Revenue Concern Narratives - Sahm
Organogenesis Q4 Earnings Call Highlights - Yahoo Finance
Organogenesis Holdings Inc (ORGO) Q4 2025 Earnings Call Highlights: Record Revenue Growth Amid ... - Investing.com Canada
Organogenesis (ORGO) Q4 2025 Earnings Transcript - AOL.com
ORGO: Record Q4 revenue, but 2026 guidance signals a sharp decline before expected recovery - TradingView
Organogenesis: Q4 Earnings Snapshot - Barchart.com
Earnings call transcript: Organogenesis Q4 2025 beats expectations but faces market challenges - Investing.com UK
Organogenesis Holdings Inc. (ORGO) Stock Rises on Q4 2025 Earnings - Quiver Quantitative
ORGO: Record 2025 results, but 2026 revenue expected to decline due to CMS changes before recovery - TradingView
Wound-care firm Organogenesis hits record sales, warns 2026 drop up to 38% - Stock Titan
Organogenesis Q4 2025 Earnings Call Transcript - MarketBeat
A Preview Of Organogenesis Hldgs's Earnings - Benzinga
Published on: 2026-02-25 08:32:12 - baoquankhu1.vn
Organogenesis Holdings Inc expected to post earnings of 21 cents a shareEarnings Preview - TradingView
Organogenesis Names Patrick McGuire Chief Accounting Officer - The Globe and Mail
Organogenesis (Nasdaq: ORGO) appoints Patrick McGuire as CAO - Stock Titan
Organogenesis Holdings Inc. Announces Executive Changes, Effective February 18, 2026 - marketscreener.com
Organogenesis (NASDAQ: ORGO) legal chief granted options, RSUs and settles taxes - Stock Titan
Executive equity awards at Organogenesis (ORGO) include RSUs, options and tax withholding - Stock Titan
Organogenesis Holdings (NASDAQ: ORGO) COO gets new stock and option awards - Stock Titan
Equity grant gives Organogenesis (ORGO) director 48,828 RSUs vesting 2027 - Stock Titan
Today's SEC FilingsLatest 10-K, 10-Q, 8-K Forms - Stock Titan
48,828 RSUs granted to Organogenesis (ORGO) director Arthur Leibowitz - Stock Titan
What’s the fair value of Organogenesis Holdings Inc. stockJuly 2025 Price Swings & Verified Momentum Stock Ideas - mfd.ru
Organogenesis Holdings Inc. (ORGO) Stock Analysis: Exploring a 113% Potential Upside in Healthcare Innovation - DirectorsTalk Interviews
Stem Cell and Regenerative Therapy Markets, 2022-2025 & Forecast to 2030 Featuring Profiles of Leading CompaniesGilead Sciences, Novartis, Bristol-Myers Squibb, Organogenesis, MiMedx Group and More - Yahoo Finance
Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 26, 2026 - The Manila Times
Regenerative medicine firm Organogenesis sets Feb. 26 call on 2025 results - Stock Titan
Organogenesis (ORGO) COO logs tax-withholding stock dispositions in Form 4 - Stock Titan
Published on: 2026-02-18 01:47:23 - mfd.ru
Organogenesis (NASDAQ: ORGO) holder First Light reports 2.85% stake - Stock Titan
Will Organogenesis Holdings Inc. benefit from rate cutsTrade Exit Report & Reliable Breakout Forecasts - mfd.ru
ORGO Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Organogenesis Holdings Inc. (ORGO) Stock Analysis: A Compelling 127% Upside Potential Amid Strong Revenue Growth - DirectorsTalk Interviews
ORGO Should I Buy - Intellectia AI
Is Organogenesis Holdings Inc. benefiting from innovation trends2025 Growth vs Value & Target Return Focused Stock Picks - mfd.ru
Soleus group holds 9.99M Organogenesis (ORGO) shares in passive stake - Stock Titan
Aug Analyst Calls: Is Organogenesis Holdings Inc. stock in correction or buying zoneTrade Risk Report & Fast Exit and Entry Trade Guides - mfd.ru
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vizsla Silver Corp. - GlobeNewswire Inc.
Is Organogenesis Holdings Inc impacted by rising ratesWeekly Trade Summary & Long Hold Capital Preservation Tips - baoquankhu1.vn
Finanzdaten der Organogenesis Holdings Inc-Aktie (ORGO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.47%
0.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):